Drug Profile
MB 110
Alternative Names: DBPR 110; MB-110; NSFA 10003S0; NSFAI003Latest Information Update: 23 Aug 2022
Price :
$50
*
At a glance
- Originator MICROBIO Group
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis C
Most Recent Events
- 23 Aug 2022 MB 110 is still in phase I trials for Hepatitis-C (MICROBIO Group pipeline, August 2022)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Hepatitis-C in Taiwan (PO)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Hepatitis-C in USA (PO)